AMGN - Amgen Inc.
| Previous close | 186.19 |
| Open | 186.25 |
| Bid | 186.53 x 900 |
| Ask | 187.75 x 900 |
| Day's range | 184.74 - 187.51 |
| 52-week range | 163.31 - 201.23 |
| Volume | 2,111,071 |
| Avg. volume | 3,254,398 |
| Market cap | 123.415B |
| Beta | 1.71 |
| PE ratio (TTM) | 61.11 |
| EPS (TTM) | 3.05 |
| Earnings date | 23 Jul 2018 - 27 Jul 2018 |
| Forward dividend & yield | 5.28 (2.85%) |
| Ex-dividend date | 2018-05-16 |
| 1y target est | 195.30 |
- Bloomberg Video•2 days ago
Trump Targets Another $200 Billion in China Goods as Tensions Intensify
Jun.18 -- President Donald Trump is threatening to slap tariffs on another $200 billion in Chinese imports as trade tensions between the world’s two largest economies reach new heights. William Zarit, chairman of the American Chamber of Commerce in China, weighs in on "Bloomberg Daybreak: Asia" with Yvonne Man.
- Zacks•15 hours ago
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
- Zacks•16 hours ago
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
- Simply Wall St.•6 days ago
Amgen Inc (NASDAQ:AMGN): Time For A Financial Health Check
The size of Amgen Inc (NASDAQ:AMGN), a US$122.46B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More...
- Zacks•7 days ago
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
- Zacks•8 days ago
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
- Motley Fool•8 days ago
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Even with falling sales, Humira should still rank as the top-selling drug in the world in 2024.
- Zacks•9 days ago
Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label
Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.
- Zacks•10 days ago
Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
- Investor's Business Daily•13 days ago
Why Alder's CEO Hire Could Indicate It's Seeking A Buyer
Alder Biopharmaceuticals likely will seek a buyer, an analyst said Thursday as shares tanked on the hire of a new chief executive.
- MarketWatch•15 days ago
Mylan shares zoom on key approval and $4.5 billion market opportunity
Being first to market helps Mylan, as does the competitive landscape for Neulasta biosimilarsBloomberg NewsHeather Bresch, chief executive officer of Mylan, speaks during an interview in New York in 2016. Mylan NV marked a major success late Monday with the first U.S. approval of a biosimilar version of Neulasta, an anti-infective used for patients undergoing cancer treatment. Biosimilar drugs are copycat versions of expensive biologic drugs, which treat complex diseases like cancer, multiple sclerosis and diabetes.
- Zacks•15 days ago
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
- Zacks•15 days ago
Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta
Mylan (MYL) and partner Biocon get a significant boost with the FDA approval for Fulphila, a biosimilar of Amgen's Neulasta.
- Investor's Business Daily•15 days ago
Mylan Spikes After FDA Approves Its Knockoff Of Amgen's Drug
Mylan spiked to a nearly eight-week high Tuesday after the FDA approved its copycat drug to Amgen's blockbuster medication Neulasta, a treatment that is used to stimulate bone marrow.
- Investor's Business Daily•15 days ago
Why Alexion's Blockbuster Franchise Is Safe From Copycats — For Now
Alexion Pharmaceuticals will likely keep 75% of its Soliris market in the U.S. even as rivals like Amgen try to copy the blockbuster drug, an analyst said Tuesday in a bullish note.
- Reuters - UK Focus•15 days ago
US STOCKS-S&P rises; technology helps Nasdaq hit intraday record
The S&P 500 edged slightly higher on Tuesday, on track for its third straight day of gains, while Nasdaq hit an intraday record high with help from the technology and consumer discretionary sectors. Amazon.com ...
- Motley Fool•15 days ago
Watch Out Amgen, Here Comes Mylan
Mylan's latest FDA approval puts it in direct competition against one of Amgen's most important drugs.
- CNBC•16 days ago
Charts point to big biotech breakout
Biotech has been quietly breaking out, now up more than 10 percent from its April lows. And one top technician sees an even bigger breakout ahead.
- MarketWatch•16 days ago
Mylan rallies on FDA approval of biotech drug similar to Amgen's
U.S. shares of Mylan NV rallied in the extended session after the drug maker received Food and Drug Administration approval for a biologic drug that is similar to one made by Amgen Inc. . Mylan ADRs surged ...
- Motley Fool•18 days ago
Is Amgen Inc. (AMGN) a Buy?
Can the big biotech continue delivering impressive returns in the coming decade?
- Motley Fool•18 days ago
3 Reasons Gilead Sciences Is a Better Value Stock Than Amgen
Amgen looks like a pretty good bargain right now, but Gilead stock is dirt cheap.
- Investor's Business Daily•19 days ago
FDA Delays Amgen-Allergan Copycat Herceptin, Gives Roche Breathing Room
Amgen and Allergan were sidelined Friday after the FDA delayed their Herceptin biosimilar, giving Roche's blockbuster breast cancer drug some breathing room.
- Reuters - UK Focus•19 days ago
Novartis readies anti-sexism message for migraine drug
With (Other OTC: WWTH - news) women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The injectable monoclonal antibody that Novartis has developed with Amgen (NasdaqGS: AMGN - news) won approval in the United States this month and on Friday bagged a recommendation from a key European panel, clearing the way for likely approval on the continent. Novartis is also considering new pricing models for Aimovig.
- Reuters•20 days ago
Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod
Novartis's (NOVN.S) generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's (ABBV.N) Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for marketing authorisation of Novartis's proposed biosimilar adalimumab. The European Commission nearly always follows the CHMP recommendation.
- Market Realist•20 days ago
GlaxoSmithKline’s Vaccines Segment in Q1 2018
GlaxoSmithKline’s (GSK) Vaccines segment includes various vaccines, including meningitis vaccines, influenza vaccines, shingles vaccines, and established vaccines. GlaxoSmithKline acquired meningitis vaccines from Novartis (NVS) in 2016.
